Parabilis Medicines, Inc. - Common Stock (PBLS)
24.44
-2.48 (-9.21%)
NASDAQ · Last Trade: Oct 25th, 10:22 AM EDT
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027marketbeat.com
Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra
Via MarketBeat · October 24, 2026
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Investedfool.com
Parabilis Medicines is ambitious, but it has Regeneron on its side already.
Via The Motley Fool · June 27, 2026
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?fool.com
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.
Via The Motley Fool · June 20, 2026
SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History.fool.com
The Elon Musk-led company has attracted investors' attention in recent days.
Via The Motley Fool · June 15, 2026
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?fool.com
It's important to consider your comfort with risk before diving in.
Via The Motley Fool · June 12, 2026